Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary
Abstract The Task Force for the Universal Definition of Myocardial Infarction recently published updated guidelines for the clinical and research diagnosis of myocardial infarction under a variety of circumstances and in a variety of categories. A type 1 myocardial infarction (MI) is usually the res...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 2014-02, Vol.127 (2), p.105-108 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108 |
|---|---|
| container_issue | 2 |
| container_start_page | 105 |
| container_title | The American journal of medicine |
| container_volume | 127 |
| creator | Alpert, Joseph S., MD Thygesen, Kristian A., MD, DSc White, Harvey D., DSc Jaffe, Allan S., MD |
| description | Abstract The Task Force for the Universal Definition of Myocardial Infarction recently published updated guidelines for the clinical and research diagnosis of myocardial infarction under a variety of circumstances and in a variety of categories. A type 1 myocardial infarction (MI) is usually the result of atherosclerotic coronary artery disease with thrombotic coronary arterial obstruction secondary to atherosclerotic plaque rupture, ulceration, fissuring, or dissection, causing coronary arterial obstruction with resultant myocardial ischemia and necrosis. Patients with a type 2 MI do not have atherosclerotic plaque rupture. In this latter group of patients, myocardial necrosis occurs because of an increase in myocardial oxygen demand or a decrease in myocardial blood flow. Type 2 MI has been the subject of considerable clinical discussion and confusion. This review by knowledgeable members of the Task Force seeks to help clinicians resolve the confusion surrounding type 2 MI. |
| doi_str_mv | 10.1016/j.amjmed.2013.09.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492698049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002934313008802</els_id><sourcerecordid>1492698049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-98b80dfca73384ecc75edbef1990bdcbc77d8467af9c1f2850ca0ab910d9cf2a3</originalsourceid><addsrcrecordid>eNqFkk2L1TAUhoMoznX0H4gU3LhpPUnTj7gQ5Pp1YUTQ69aQJiea2jY1aZX77029MwizcRUOec6bnCch5DGFggKtn_eFGvsRTcGAlgWIAkp6h-xoVVV5Q2t2l-wAgOWi5OUFeRBjn0oQVX2fXDDO69RGd-Tra6e-TT4uTmdqMtnxOwY147rVh3EenFaL81PMvM2Opxkzln04ea2CcWrIDpNVQW_Ai-wT_nL4-2_I3o8jTosKp4fknlVDxEfX6yX58vbNcf8-v_r47rB_dZXritIlF23XgrFaNWXZctS6qdB0aKkQ0Bnd6aYxLa8bZYWmlrUVaAWqExSM0Jap8pI8O-fOwf9cMS5ydFHjMKgJ_Rol5YLVogUuEvr0Ftr7NUzpdhvVVrzhnCaKnykdfIwBrZyDG9NEkoLc_Mtenv3Lzb8EIZP_1PbkOnzttr2bphvhCXh5BjDZSMKCjNrhpNG4gHqRxrv_nXA7QA9uSs80_MATxn-zyMgkyM_bH9i-AC0B2hZY-QepwK1b</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1498547441</pqid></control><display><type>article</type><title>Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Alpert, Joseph S., MD ; Thygesen, Kristian A., MD, DSc ; White, Harvey D., DSc ; Jaffe, Allan S., MD</creator><creatorcontrib>Alpert, Joseph S., MD ; Thygesen, Kristian A., MD, DSc ; White, Harvey D., DSc ; Jaffe, Allan S., MD</creatorcontrib><description>Abstract The Task Force for the Universal Definition of Myocardial Infarction recently published updated guidelines for the clinical and research diagnosis of myocardial infarction under a variety of circumstances and in a variety of categories. A type 1 myocardial infarction (MI) is usually the result of atherosclerotic coronary artery disease with thrombotic coronary arterial obstruction secondary to atherosclerotic plaque rupture, ulceration, fissuring, or dissection, causing coronary arterial obstruction with resultant myocardial ischemia and necrosis. Patients with a type 2 MI do not have atherosclerotic plaque rupture. In this latter group of patients, myocardial necrosis occurs because of an increase in myocardial oxygen demand or a decrease in myocardial blood flow. Type 2 MI has been the subject of considerable clinical discussion and confusion. This review by knowledgeable members of the Task Force seeks to help clinicians resolve the confusion surrounding type 2 MI.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/j.amjmed.2013.09.031</identifier><identifier>PMID: 24462011</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Atherosclerosis ; Biomarkers - blood ; Blood Pressure ; Clinical definition ; Coronary Circulation ; Electrocardiography ; Gangrene ; Heart attacks ; Humans ; Internal Medicine ; Ischemia ; Medical diagnosis ; Myocardial infarction ; Myocardial Infarction - blood ; Myocardial Infarction - diagnosis ; Myocardial Infarction - metabolism ; Myocardial Infarction - physiopathology ; Myocardial Infarction - therapy ; Myocardium - metabolism ; Myocardium - pathology ; Necrosis ; Oxygen Consumption ; Troponin ; Troponin - blood</subject><ispartof>The American journal of medicine, 2014-02, Vol.127 (2), p.105-108</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Feb 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-98b80dfca73384ecc75edbef1990bdcbc77d8467af9c1f2850ca0ab910d9cf2a3</citedby><cites>FETCH-LOGICAL-c511t-98b80dfca73384ecc75edbef1990bdcbc77d8467af9c1f2850ca0ab910d9cf2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.amjmed.2013.09.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24462011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alpert, Joseph S., MD</creatorcontrib><creatorcontrib>Thygesen, Kristian A., MD, DSc</creatorcontrib><creatorcontrib>White, Harvey D., DSc</creatorcontrib><creatorcontrib>Jaffe, Allan S., MD</creatorcontrib><title>Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>Abstract The Task Force for the Universal Definition of Myocardial Infarction recently published updated guidelines for the clinical and research diagnosis of myocardial infarction under a variety of circumstances and in a variety of categories. A type 1 myocardial infarction (MI) is usually the result of atherosclerotic coronary artery disease with thrombotic coronary arterial obstruction secondary to atherosclerotic plaque rupture, ulceration, fissuring, or dissection, causing coronary arterial obstruction with resultant myocardial ischemia and necrosis. Patients with a type 2 MI do not have atherosclerotic plaque rupture. In this latter group of patients, myocardial necrosis occurs because of an increase in myocardial oxygen demand or a decrease in myocardial blood flow. Type 2 MI has been the subject of considerable clinical discussion and confusion. This review by knowledgeable members of the Task Force seeks to help clinicians resolve the confusion surrounding type 2 MI.</description><subject>Atherosclerosis</subject><subject>Biomarkers - blood</subject><subject>Blood Pressure</subject><subject>Clinical definition</subject><subject>Coronary Circulation</subject><subject>Electrocardiography</subject><subject>Gangrene</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Ischemia</subject><subject>Medical diagnosis</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - blood</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocardial Infarction - therapy</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>Necrosis</subject><subject>Oxygen Consumption</subject><subject>Troponin</subject><subject>Troponin - blood</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk2L1TAUhoMoznX0H4gU3LhpPUnTj7gQ5Pp1YUTQ69aQJiea2jY1aZX77029MwizcRUOec6bnCch5DGFggKtn_eFGvsRTcGAlgWIAkp6h-xoVVV5Q2t2l-wAgOWi5OUFeRBjn0oQVX2fXDDO69RGd-Tra6e-TT4uTmdqMtnxOwY147rVh3EenFaL81PMvM2Opxkzln04ea2CcWrIDpNVQW_Ai-wT_nL4-2_I3o8jTosKp4fknlVDxEfX6yX58vbNcf8-v_r47rB_dZXritIlF23XgrFaNWXZctS6qdB0aKkQ0Bnd6aYxLa8bZYWmlrUVaAWqExSM0Jap8pI8O-fOwf9cMS5ydFHjMKgJ_Rol5YLVogUuEvr0Ftr7NUzpdhvVVrzhnCaKnykdfIwBrZyDG9NEkoLc_Mtenv3Lzb8EIZP_1PbkOnzttr2bphvhCXh5BjDZSMKCjNrhpNG4gHqRxrv_nXA7QA9uSs80_MATxn-zyMgkyM_bH9i-AC0B2hZY-QepwK1b</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Alpert, Joseph S., MD</creator><creator>Thygesen, Kristian A., MD, DSc</creator><creator>White, Harvey D., DSc</creator><creator>Jaffe, Allan S., MD</creator><general>Elsevier Inc</general><general>Elsevier Sequoia S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20140201</creationdate><title>Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary</title><author>Alpert, Joseph S., MD ; Thygesen, Kristian A., MD, DSc ; White, Harvey D., DSc ; Jaffe, Allan S., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-98b80dfca73384ecc75edbef1990bdcbc77d8467af9c1f2850ca0ab910d9cf2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Atherosclerosis</topic><topic>Biomarkers - blood</topic><topic>Blood Pressure</topic><topic>Clinical definition</topic><topic>Coronary Circulation</topic><topic>Electrocardiography</topic><topic>Gangrene</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Ischemia</topic><topic>Medical diagnosis</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - blood</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocardial Infarction - therapy</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>Necrosis</topic><topic>Oxygen Consumption</topic><topic>Troponin</topic><topic>Troponin - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alpert, Joseph S., MD</creatorcontrib><creatorcontrib>Thygesen, Kristian A., MD, DSc</creatorcontrib><creatorcontrib>White, Harvey D., DSc</creatorcontrib><creatorcontrib>Jaffe, Allan S., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alpert, Joseph S., MD</au><au>Thygesen, Kristian A., MD, DSc</au><au>White, Harvey D., DSc</au><au>Jaffe, Allan S., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>127</volume><issue>2</issue><spage>105</spage><epage>108</epage><pages>105-108</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>Abstract The Task Force for the Universal Definition of Myocardial Infarction recently published updated guidelines for the clinical and research diagnosis of myocardial infarction under a variety of circumstances and in a variety of categories. A type 1 myocardial infarction (MI) is usually the result of atherosclerotic coronary artery disease with thrombotic coronary arterial obstruction secondary to atherosclerotic plaque rupture, ulceration, fissuring, or dissection, causing coronary arterial obstruction with resultant myocardial ischemia and necrosis. Patients with a type 2 MI do not have atherosclerotic plaque rupture. In this latter group of patients, myocardial necrosis occurs because of an increase in myocardial oxygen demand or a decrease in myocardial blood flow. Type 2 MI has been the subject of considerable clinical discussion and confusion. This review by knowledgeable members of the Task Force seeks to help clinicians resolve the confusion surrounding type 2 MI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24462011</pmid><doi>10.1016/j.amjmed.2013.09.031</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 2014-02, Vol.127 (2), p.105-108 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1492698049 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Atherosclerosis Biomarkers - blood Blood Pressure Clinical definition Coronary Circulation Electrocardiography Gangrene Heart attacks Humans Internal Medicine Ischemia Medical diagnosis Myocardial infarction Myocardial Infarction - blood Myocardial Infarction - diagnosis Myocardial Infarction - metabolism Myocardial Infarction - physiopathology Myocardial Infarction - therapy Myocardium - metabolism Myocardium - pathology Necrosis Oxygen Consumption Troponin Troponin - blood |
| title | Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A45%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20Therapeutic%20Implications%20of%20Type%202%20Myocardial%20Infarction:%20Review%20and%20Commentary&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Alpert,%20Joseph%20S.,%20MD&rft.date=2014-02-01&rft.volume=127&rft.issue=2&rft.spage=105&rft.epage=108&rft.pages=105-108&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/j.amjmed.2013.09.031&rft_dat=%3Cproquest_cross%3E1492698049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1498547441&rft_id=info:pmid/24462011&rft_els_id=S0002934313008802&rfr_iscdi=true |